HEADER PROTEIN BINDING 24-JAN-23 8CA0 TITLE MACROPHAGE INHIBITORY FACTOR (MIF) IN COMPLEX WITH SMALL MOLECULE TITLE 2 PAV174 COMPND MOL_ID: 1; COMPND 2 MOLECULE: MACROPHAGE MIGRATION INHIBITORY FACTOR; COMPND 3 CHAIN: A, B, C; COMPND 4 SYNONYM: MIF,GLYCOSYLATION-INHIBITING FACTOR,GIF,L-DOPACHROME COMPND 5 ISOMERASE,L-DOPACHROME TAUTOMERASE,PHENYLPYRUVATE TAUTOMERASE; COMPND 6 EC: 5.3.2.1,5.3.3.12; COMPND 7 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: MIF, GLIF, MMIF; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 562 KEYWDS MIF, OXMIF, HERPES, ALZHEIMER'S DISEASE, PROTEIN BINDING EXPDTA SOLUTION NMR NUMMDL 4 AUTHOR A.MUELLER,F.TORRES,R.ROLAND,C.KORTH REVDAT 1 07-FEB-24 8CA0 0 JRNL AUTH A.MUELLER-SCHIFFMANN,F.TORRES,A.KITAYGORODSKYY,A.RAMANI, JRNL AUTH 2 A.ALATZA,S.TSCHIRNER,I.PRIKULIS,S.YU,D.DEY,S.MALLESH, JRNL AUTH 3 D.PRASAD,D.SOLAS,V.BADER,A.ROZEMULLER,S.WRAY, JRNL AUTH 4 J.GOPALAKRISHNAN,R.RIEK,V.R.LINGAPPA,C.KORTH JRNL TITL OXIDIZED MIF IS A DRUG TARGET AT THE MOLECULAR INTERSECTION JRNL TITL 2 BETWEEN IMMUNE ACTIVATION AND TAU CELLULAR PATHOLOGY JRNL REF TO BE PUBLISHED JRNL REFN REMARK 2 REMARK 2 RESOLUTION. NOT APPLICABLE. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : HADDOCK REMARK 3 AUTHORS : ALEXANDRE BONVIN, UNIVERSITY UTRECHT REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 8CA0 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 08-MAR-23. REMARK 100 THE DEPOSITION ID IS D_1292128100. REMARK 210 REMARK 210 EXPERIMENTAL DETAILS REMARK 210 EXPERIMENT TYPE : NMR REMARK 210 TEMPERATURE (KELVIN) : 298 REMARK 210 PH : 7.2 REMARK 210 IONIC STRENGTH : 20 REMARK 210 PRESSURE : 1 PA REMARK 210 SAMPLE CONTENTS : 1.0 MM [U-13C; U-15N] MIF, 1.0 REMARK 210 MM PAV, 100% D2O REMARK 210 REMARK 210 NMR EXPERIMENTS CONDUCTED : 2D 1H-1H NOESY REMARK 210 SPECTROMETER FIELD STRENGTH : 700 MHZ REMARK 210 SPECTROMETER MODEL : AVANCE NEO REMARK 210 SPECTROMETER MANUFACTURER : BRUKER REMARK 210 REMARK 210 STRUCTURE DETERMINATION. REMARK 210 SOFTWARE USED : CCPNMR ANALYSIS, CYANA REMARK 210 METHOD USED : SIMULATED ANNEALING REMARK 210 REMARK 210 CONFORMERS, NUMBER CALCULATED : 4 REMARK 210 CONFORMERS, NUMBER SUBMITTED : 4 REMARK 210 CONFORMERS, SELECTION CRITERIA : TARGET FUNCTION REMARK 210 REMARK 210 BEST REPRESENTATIVE CONFORMER IN THIS ENSEMBLE : 1 REMARK 210 REMARK 210 REMARK: NULL REMARK 215 REMARK 215 NMR STUDY REMARK 215 THE COORDINATES IN THIS ENTRY WERE GENERATED FROM SOLUTION REMARK 215 NMR DATA. PROTEIN DATA BANK CONVENTIONS REQUIRE THAT REMARK 215 CRYST1 AND SCALE RECORDS BE INCLUDED, BUT THE VALUES ON REMARK 215 THESE RECORDS ARE MEANINGLESS. REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: TRIMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B, C REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 HA PRO C 91 HG22 VAL C 94 1.32 REMARK 500 HB3 MET B 47 HD2 HIS C 40 1.34 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 1 ASP A 44 74.76 57.11 REMARK 500 1 SER A 53 46.48 -78.91 REMARK 500 1 ASN A 109 97.89 64.52 REMARK 500 1 GLN B 45 -163.28 -123.83 REMARK 500 1 ASN B 105 45.41 -105.35 REMARK 500 1 TRP B 108 110.07 77.55 REMARK 500 1 ASN B 109 90.73 63.70 REMARK 500 1 PRO C 55 94.42 -58.63 REMARK 500 1 ARG C 86 -54.00 -125.37 REMARK 500 2 GLN A 28 32.68 -84.58 REMARK 500 2 ALA A 29 -56.81 -139.96 REMARK 500 2 LYS A 66 77.87 60.89 REMARK 500 2 ASN A 109 98.13 66.22 REMARK 500 2 SER A 111 -167.90 -124.91 REMARK 500 2 MET B 2 -155.36 -87.58 REMARK 500 2 ASP B 44 79.99 67.93 REMARK 500 2 TRP B 108 124.73 73.04 REMARK 500 2 ASN B 109 66.52 64.10 REMARK 500 2 ASN B 110 75.83 50.25 REMARK 500 3 PRO A 43 -163.74 -101.57 REMARK 500 3 ASN A 109 95.83 67.91 REMARK 500 3 ASN B 105 76.38 -110.17 REMARK 500 3 VAL B 106 -159.41 -91.67 REMARK 500 3 ASN B 109 80.60 64.17 REMARK 500 3 ASN B 110 62.26 61.62 REMARK 500 3 SER C 53 37.39 -87.22 REMARK 500 3 PRO C 55 98.52 -56.65 REMARK 500 4 ASN A 109 99.52 65.78 REMARK 500 4 MET B 2 -155.80 -105.40 REMARK 500 4 ASP B 44 60.73 62.04 REMARK 500 4 ASN B 105 74.36 -114.30 REMARK 500 4 ASN B 109 111.79 64.28 REMARK 500 4 SER C 53 37.08 -90.49 REMARK 500 4 PRO C 55 88.12 -62.21 REMARK 500 4 ILE C 64 68.10 -113.83 REMARK 500 4 ARG C 93 30.78 -146.89 REMARK 500 4 ASN C 109 60.66 65.04 REMARK 500 4 ASN C 110 -55.25 71.49 REMARK 500 REMARK 500 REMARK: NULL REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 34783 RELATED DB: BMRB REMARK 900 MACROPHAGE INHIBITORY FACTOR (MIF) IN COMPLEX WITH SMALL MOLECULE REMARK 900 PAV174 DBREF 8CA0 A 1 114 UNP P14174 MIF_HUMAN 2 115 DBREF 8CA0 B 1 114 UNP P14174 MIF_HUMAN 2 115 DBREF 8CA0 C 1 114 UNP P14174 MIF_HUMAN 2 115 SEQRES 1 A 114 PRO MET PHE ILE VAL ASN THR ASN VAL PRO ARG ALA SER SEQRES 2 A 114 VAL PRO ASP GLY PHE LEU SER GLU LEU THR GLN GLN LEU SEQRES 3 A 114 ALA GLN ALA THR GLY LYS PRO PRO GLN TYR ILE ALA VAL SEQRES 4 A 114 HIS VAL VAL PRO ASP GLN LEU MET ALA PHE GLY GLY SER SEQRES 5 A 114 SER GLU PRO CYS ALA LEU CYS SER LEU HIS SER ILE GLY SEQRES 6 A 114 LYS ILE GLY GLY ALA GLN ASN ARG SER TYR SER LYS LEU SEQRES 7 A 114 LEU CYS GLY LEU LEU ALA GLU ARG LEU ARG ILE SER PRO SEQRES 8 A 114 ASP ARG VAL TYR ILE ASN TYR TYR ASP MET ASN ALA ALA SEQRES 9 A 114 ASN VAL GLY TRP ASN ASN SER THR PHE ALA SEQRES 1 B 114 PRO MET PHE ILE VAL ASN THR ASN VAL PRO ARG ALA SER SEQRES 2 B 114 VAL PRO ASP GLY PHE LEU SER GLU LEU THR GLN GLN LEU SEQRES 3 B 114 ALA GLN ALA THR GLY LYS PRO PRO GLN TYR ILE ALA VAL SEQRES 4 B 114 HIS VAL VAL PRO ASP GLN LEU MET ALA PHE GLY GLY SER SEQRES 5 B 114 SER GLU PRO CYS ALA LEU CYS SER LEU HIS SER ILE GLY SEQRES 6 B 114 LYS ILE GLY GLY ALA GLN ASN ARG SER TYR SER LYS LEU SEQRES 7 B 114 LEU CYS GLY LEU LEU ALA GLU ARG LEU ARG ILE SER PRO SEQRES 8 B 114 ASP ARG VAL TYR ILE ASN TYR TYR ASP MET ASN ALA ALA SEQRES 9 B 114 ASN VAL GLY TRP ASN ASN SER THR PHE ALA SEQRES 1 C 114 PRO MET PHE ILE VAL ASN THR ASN VAL PRO ARG ALA SER SEQRES 2 C 114 VAL PRO ASP GLY PHE LEU SER GLU LEU THR GLN GLN LEU SEQRES 3 C 114 ALA GLN ALA THR GLY LYS PRO PRO GLN TYR ILE ALA VAL SEQRES 4 C 114 HIS VAL VAL PRO ASP GLN LEU MET ALA PHE GLY GLY SER SEQRES 5 C 114 SER GLU PRO CYS ALA LEU CYS SER LEU HIS SER ILE GLY SEQRES 6 C 114 LYS ILE GLY GLY ALA GLN ASN ARG SER TYR SER LYS LEU SEQRES 7 C 114 LEU CYS GLY LEU LEU ALA GLU ARG LEU ARG ILE SER PRO SEQRES 8 C 114 ASP ARG VAL TYR ILE ASN TYR TYR ASP MET ASN ALA ALA SEQRES 9 C 114 ASN VAL GLY TRP ASN ASN SER THR PHE ALA HET VIU A 201 55 HETNAM VIU 1-ETHYL-9-METHYL-3,7-DIPYRROLIDIN-1-YL-PHENOTHIAZINE FORMUL 4 VIU C23 H29 N3 S HELIX 1 AA1 PRO A 10 VAL A 14 5 5 HELIX 2 AA2 GLY A 17 GLY A 31 1 15 HELIX 3 AA3 PRO A 33 TYR A 36 5 4 HELIX 4 AA4 ALA A 70 LEU A 87 1 18 HELIX 5 AA5 SER A 90 ASP A 92 5 3 HELIX 6 AA6 ASN A 102 VAL A 106 5 5 HELIX 7 AA7 PRO B 10 VAL B 14 5 5 HELIX 8 AA8 GLY B 17 GLY B 31 1 15 HELIX 9 AA9 PRO B 33 TYR B 36 5 4 HELIX 10 AB1 GLY B 68 LEU B 87 1 20 HELIX 11 AB2 SER B 90 ASP B 92 5 3 HELIX 12 AB3 PRO C 10 VAL C 14 5 5 HELIX 13 AB4 SER C 20 GLY C 31 1 12 HELIX 14 AB5 PRO C 33 TYR C 36 5 4 HELIX 15 AB6 GLY C 68 ARG C 88 1 21 HELIX 16 AB7 SER C 90 ARG C 93 5 4 HELIX 17 AB8 ASN C 102 ALA C 104 5 3 SHEET 1 AA1 6 THR B 112 PHE B 113 0 SHEET 2 AA1 6 VAL A 94 ASN A 97 1 N ILE A 96 O PHE B 113 SHEET 3 AA1 6 ALA A 57 HIS A 62 1 N LEU A 61 O ASN A 97 SHEET 4 AA1 6 MET A 2 THR A 7 -1 N ASN A 6 O LEU A 58 SHEET 5 AA1 6 ALA A 38 VAL A 42 1 O ALA A 38 N PHE A 3 SHEET 6 AA1 6 LEU C 46 PHE C 49 -1 O ALA C 48 N VAL A 39 SHEET 1 AA2 2 MET A 47 PHE A 49 0 SHEET 2 AA2 2 ALA B 38 HIS B 40 -1 O VAL B 39 N ALA A 48 SHEET 1 AA3 2 SER A 111 THR A 112 0 SHEET 2 AA3 2 TYR C 95 ILE C 96 1 O ILE C 96 N SER A 111 SHEET 1 AA4 2 LEU B 46 PHE B 49 0 SHEET 2 AA4 2 ALA C 38 VAL C 41 -1 O VAL C 39 N ALA B 48 SHEET 1 AA5 4 ALA B 57 SER B 63 0 SHEET 2 AA5 4 VAL B 94 ASP B 100 1 O ASN B 97 N LEU B 61 SHEET 3 AA5 4 VAL C 106 TRP C 108 -1 O GLY C 107 N ILE B 96 SHEET 4 AA5 4 SER C 111 THR C 112 -1 O SER C 111 N TRP C 108 SHEET 1 AA6 2 ASN C 6 THR C 7 0 SHEET 2 AA6 2 ALA C 57 LEU C 58 -1 O LEU C 58 N ASN C 6 SHEET 1 AA7 2 LEU C 61 HIS C 62 0 SHEET 2 AA7 2 TYR C 98 TYR C 99 1 O TYR C 99 N LEU C 61 CRYST1 1.000 1.000 1.000 90.00 90.00 90.00 P 1 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 1.000000 0.000000 0.000000 0.00000 SCALE2 0.000000 1.000000 0.000000 0.00000 SCALE3 0.000000 0.000000 1.000000 0.00000 MODEL 1